NASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis $10.07 -0.03 (-0.30%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.00▼$10.5150-Day Range$7.24▼$10.7752-Week Range$1.76▼$13.17Volume1.46 million shsAverage Volume3.86 million shsMarket Capitalization$1.17 billionP/E RatioN/ADividend YieldN/APrice Target$23.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Arcutis Biotherapeutics alerts: Email Address Arcutis Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside134.1% Upside$23.57 Price TargetShort InterestBearish19.57% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 5 Articles This WeekInsider TradingSelling Shares$378,950 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.60) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.31 out of 5 starsMedical Sector771st out of 936 stocksPharmaceutical Preparations Industry357th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingArcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageArcutis Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Arcutis Biotherapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.57% of the outstanding shares of Arcutis Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently increased by 6.19%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARQT. Previous Next 2.4 News and Social Media Coverage News SentimentArcutis Biotherapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Arcutis Biotherapeutics this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for ARQT on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows14 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $378,950.00 in company stock.Percentage Held by InsidersOnly 9.50% of the stock of Arcutis Biotherapeutics is held by insiders.Read more about Arcutis Biotherapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($1.60) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 10.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arcutis Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Arcutis Biotherapeutics Stock (NASDAQ:ARQT)Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Read More ARQT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARQT Stock News HeadlinesJuly 3, 2024 | insidertrades.comInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Sells 10,000 Shares of StockJuly 23 at 2:57 PM | investorplace.com7 Biotech Stocks to Keep on Your Clinical RadarJuly 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” July 22, 2024 | globenewswire.comArcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOLJuly 17, 2024 | americanbankingnews.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives $25.38 Average Target Price from AnalystsJuly 9, 2024 | globenewswire.comFDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of AgeJuly 6, 2024 | investorplace.comThe 7 Best Under $10 Stocks to Buy in July 2024July 3, 2024 | globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” June 13, 2024 | investorplace.comHave $5-10? 7 Affordable Stocks That Are About to Breakout.June 10, 2024 | globenewswire.comArcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema ConferenceJune 5, 2024 | globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 24, 2024 | finance.yahoo.comAnalysts Are Betting On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) With A Big Upgrade This WeekMay 20, 2024 | seekingalpha.comArcutis Stock: Sales Expansion Momentum Puts It On A Good TrajectoryMay 15, 2024 | markets.businessinsider.comUpgraded Buy Rating and Price Target for Arcutis Biotherapeutics Amid Zoryve’s Robust Sales PerformanceMay 15, 2024 | msn.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finance.yahoo.comQ1 2024 Arcutis Biotherapeutics Inc Earnings CallMay 15, 2024 | markets.businessinsider.comA Balanced Outlook: Maintaining Hold on Arcutis Amidst Zoryve’s Mixed Performance and Potential Growth CatalystsSee More Headlines Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARQT CUSIPN/A CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees150Year Founded2016Price Target and Rating Average Stock Price Target$23.57 High Stock Price Target$50.00 Low Stock Price Target$8.00 Potential Upside/Downside+134.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-262,140,000.00 Net Margins-204.35% Pretax Margin-201.12% Return on Equity-197.28% Return on Assets-60.67% Debt Debt-to-Equity Ratio0.90 Current Ratio9.89 Quick Ratio9.61 Sales & Book Value Annual Sales$59.61 million Price / Sales19.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book10.71Miscellaneous Outstanding Shares115,760,000Free Float104,766,000Market Cap$1.17 billion OptionableOptionable Beta1.18 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Todd Franklin Watanabe M.A. (Age 56)President, CEO & Director Comp: $1.01MDr. Bhaskar Chaudhuri Ph.D. (Age 69)Co-Founder & Independent Director Comp: $60.83kDr. Patrick E. Burnett M.D. (Age 52)Ph.D., Senior VP & Chief Medical Officer Comp: $722.94kMr. L. Todd Edwards (Age 60)Senior VP & Chief Commercial Officer Comp: $755.64kMr. David J. Topper (Age 66)Senior VP & Chief Financial Officer Mr. Rajvir MadanChief Digital & Technology OfficerMs. Latha VairavanVice President of Finance & Investor RelationsMs. Courtney Barton (Age 41)VP and Chief Compliance Officer & Privacy Officer Mr. Masaru Matsuda Esq. (Age 53)J.D., Senior VP, General Counsel & Corporate Secretary Comp: $626.22kMs. Amanda SheldonHead of Corporate CommunicationsMore ExecutivesKey CompetitorsInnovivaNASDAQ:INVAORIC PharmaceuticalsNASDAQ:ORICPhathom PharmaceuticalsNASDAQ:PHATSupernus PharmaceuticalsNASDAQ:SUPNNkartaNASDAQ:NKTXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 80,078 shares on 7/26/2024Ownership: 0.337%Legato Capital Management LLCBought 56,208 shares on 7/26/2024Ownership: 0.049%AMI Asset Management CorpSold 181,045 shares on 7/25/2024Ownership: 0.142%SG Americas Securities LLCBought 83,452 shares on 7/12/2024Ownership: 0.086%CWM LLCBought 4,044 shares on 7/10/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions ARQT Stock Analysis - Frequently Asked Questions How have ARQT shares performed this year? Arcutis Biotherapeutics' stock was trading at $3.23 on January 1st, 2024. Since then, ARQT shares have increased by 211.8% and is now trading at $10.07. View the best growth stocks for 2024 here. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) released its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.28. The firm earned $49.57 million during the quarter. Arcutis Biotherapeutics had a negative trailing twelve-month return on equity of 197.28% and a negative net margin of 204.35%. When did Arcutis Biotherapeutics IPO? Arcutis Biotherapeutics (ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Cantor was co-manager. Who are Arcutis Biotherapeutics' major shareholders? Arcutis Biotherapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.34%), AMI Asset Management Corp (0.14%), SG Americas Securities LLC (0.09%) and Legato Capital Management LLC (0.05%). Insiders that own company stock include Life Sciences Viii L Frazier, Orbimed Advisors Llc, Todd Franklin Watanabe, David W Osborne, Patrick Burnett, Masaru Matsuda, Howard G Welgus, Larry Todd Edwards, Patricia A Turney and Scott L Burrows. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX) and BioNTech (BNTX). This page (NASDAQ:ARQT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARQT Stock Alerts